• 1. Evolution in surface coverage of CH3NH3PbI3?XClXvia heat assisted solvent vapour treatment and their effects on photovoltaic performance of devices
  Dhirendra K. Chaudhary,Pramendra Kumar,Lokendra Kumar RSC Adv., 2016,6, 94731-94738
• 2. Dissociative dynamics of O2 on Ag(110)?
  Ivor Lon?ari? Phys. Chem. Chem. Phys., 2015,17, 9436-9445
• 3. Evolving better nanoparticles: Genetic algorithms for optimising cluster geometries
  Dalton Trans., 2003, 4193-4207
• 4. Emulsion soft templating of carbide-derived carbon nanospheres with controllable porosity for capacitive electrochemical energy storage?
  M. Zeiger,N. J?ckel,P. Strubel,L. Borchardt,R. Reinhold,W. Nickel,J. Eckert,V. Presser,S. Kaskel J. Mater. Chem. A, 2015,3, 17983-17990
• 5. Evolved polymerases facilitate selection of fully 2′-OMe-modified aptamers?
  Zhixia Liu,Tingjian Chen,Floyd E. Romesberg Chem. Sci., 2017,8, 8179-8182

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyridines and derivatives Pyridinecarboxylic acids
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyridines and derivatives Pyridinecarboxylic acids and derivatives Pyridinecarboxylic acids

Research Brief on 2-(Thiophen-2-yl)isonicotinic Acid (CAS: 893723-57-4): Recent Advances and Applications

2-(Thiophen-2-yl)isonicotinic acid (CAS: 893723-57-4) is a heterocyclic compound that has garnered significant attention in the field of chemical biology and medicinal chemistry due to its unique structural properties and potential therapeutic applications. Recent studies have explored its role as a key intermediate in the synthesis of novel bioactive molecules, particularly in the development of kinase inhibitors and anti-inflammatory agents. This research brief aims to summarize the latest findings related to this compound, highlighting its synthetic utility, biological activities, and potential clinical relevance.

One of the most notable advancements in the study of 2-(thiophen-2-yl)isonicotinic acid is its application in the design of small-molecule inhibitors targeting protein kinases. A 2023 study published in the Journal of Medicinal Chemistry demonstrated that derivatives of this compound exhibit potent inhibitory activity against fibroblast growth factor receptors (FGFRs), which are implicated in various cancers. The researchers utilized structure-activity relationship (SAR) analysis to optimize the compound's binding affinity, leading to the identification of several promising candidates for further preclinical evaluation.

In addition to its role in kinase inhibition, 2-(thiophen-2-yl)isonicotinic acid has been investigated for its anti-inflammatory properties. A recent Bioorganic & Medicinal Chemistry Letters publication reported that this compound acts as a modulator of the NLRP3 inflammasome, a key player in inflammatory diseases such as gout and Alzheimer's disease. The study revealed that the thiophene and isonicotinic acid moieties synergistically contribute to the compound's ability to suppress pro-inflammatory cytokine release, suggesting its potential as a lead structure for anti-inflammatory drug development.

From a synthetic chemistry perspective, 2-(thiophen-2-yl)isonicotinic acid has been employed as a versatile building block for the construction of complex heterocyclic scaffolds. A 2022 Organic Letters article detailed a novel palladium-catalyzed cross-coupling strategy that enables the efficient functionalization of this compound, opening new avenues for the diversification of its derivatives. This methodological advancement has significant implications for the rapid generation of compound libraries for high-throughput screening in drug discovery programs.

Despite these promising developments, challenges remain in the optimization of 2-(thiophen-2-yl)isonicotinic acid-based therapeutics. Pharmacokinetic studies have indicated that some derivatives exhibit limited bioavailability, prompting ongoing research into prodrug strategies and formulation technologies to improve their drug-like properties. Furthermore, the precise molecular mechanisms underlying its biological activities require further elucidation through advanced biophysical and computational modeling approaches.

In conclusion, 2-(thiophen-2-yl)isonicotinic acid (CAS: 893723-57-4) represents a valuable chemical entity with diverse applications in medicinal chemistry and drug discovery. Recent research has underscored its potential as a scaffold for the development of kinase inhibitors and anti-inflammatory agents, while synthetic innovations have expanded its utility as a building block for heterocyclic chemistry. Future studies should focus on addressing the current limitations and exploring its broader therapeutic potential across multiple disease areas.

• 851546-83-3(2-Thiophen-2-yl-quinoline-4-carboxylic acid)
• 31792-49-1(6-Methyl-2-(thiophen-2-yl)quinoline-4-carboxylic acid)
• 179408-53-8(3-Pyridinecarboxylicacid, 6-(2-thienyl)-, methyl ester)
• 33289-45-1(8-Methyl-2-(thiophen-2-yl)quinoline-4-carboxylic acid)
• 33289-51-9(6-Chloro-2-(thiophen-2-yl)quinoline-4-carboxylic acid)
• 73775-26-5(2-(5-Methylthien-2-yl)quinoline-4-carboxylic acid)
• 179408-54-9(6-(2-Thienyl)nicotinic Acid)
• 31792-47-9(2-(thiophen-2-yl)quinoline-4-carboxylic acid)
• 667412-63-7(8-Methyl-2-(5-methylthien-2-yl)quinoline-4-carboxylic Acid)
• 438216-88-7(6-Methyl-2-(5-methyl-2-thienyl)quinoline-4-carboxylic Acid)